Corona Remedies Limited · NSE:CORONA
Corona Remedies — Q1 FY27 Earnings Presentation
34 slides from Corona Remedies's earnings presentation, Jul 31, 2026
Slide 1: Cover letter to stock exchanges: Presentation to Analyst / Investor
July 31, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL:
Slide 2: CORONA Remedies Limited Investor Presentation: July 2026
CORONA Remedies Limited Investor Presentation: July 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by CORONA Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q1 FY27 About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Annexures Management Team
Slide 5: Key Highlights for Q1FY27
Key Highlights for Q1FY27 Financial Highlights - Q1FY27(Y-o- Return Ratios Key Highlights Y) Fastest growing company in top INR 422.4 Cr 50.2% 30 Pharma companies in IPM R EVEN U E MAT June-26 & Quarter ended +21.9% ROCE # June-26. [1] Improved our Rank to 26th in MAT June-26 from 27th in MAT Ma
Slide 6: Commercialized India's Most Advanced EU-GMP Approved Women's Hormone Manufacturing Facility
Commercialized India's Most Advanced EU-GMP Approved Women's Hormone Manufacturing Facility Key Highlights Growing Need for Women's Healthcare Increasing hormonal disorder, demand for fertility care, focus on menopause management and hormone replacement therapies State of the Art Manufacturing Ecosy
Slide 7: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ Crores) Q1FY27 Q1FY26 Y-o-Y Revenue from Operations 422.4 346.5 21.9% Gross Margin (%) 81.6% 81.0% Employee Cost 122.1 97.4 Other Expenses 129.7 113.5 EBITDA 93.1 69.8 33.5% EBITDA Margin (%) 22.0% 20.1% 190 bps Depreciation & Amortization 13.2
Slide 8: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and FY27 Annexures Management
Slide 9: CORONA's 3C Philosophy
CORONA’s 3C Philosophy Culture • Ruthless Execution • Internal Promotion • Adaptability • Humbleness Courage CORONA’s • Accepting Mistakes 3C and improving • Robust Inorganic Philosophy Opportunities Commitment • Global Quality Products • Value Creation for Stakeholders • Long Term Sustainable Growt
Slide 10: Journey over the years
Journey over the years In -licensing Acquisition of 7 brands arrangement with from Bayer Zydus Ferring Pharma Ltd Pharmaceuticals Listing on NSE & BSE in Private Limited to December 2025 market certain products Launch of 1st Received EAEU GMP Founded in 2004 under women’s health cardiologi
Slide 11: CORONA Remedies at a Glance
CORONA Remedies at a Glance 18.4% Jumped 6 97% 73.4% Revenue growth 1 ranks in 3 Revenue from India Chronic portfolio years Business contribution 1.9x growth compared Over MAT Jun-23 to for Q1FY27 for Q1FY27 to IPM 1 MAT Jun-26 EU-GMP, EAEU- #5 in Women’s Healthcare GMP & WHO- Commercialized 79 Bran
Slide 12: CORONA's Competitive Edge Lies in Execution Excellence
CORONA’s Competitive Edge Lies in Execution Excellence Fastest Growing in Indian Pharmaceutical Market (IPM) 18.4% Revenue MAT Growth — Fastest Growth Among Top 30 Indian Pharma Peers, Climbing 6 Ranks in 3 Years* Market Share Gains & New Launches Consistently delivering volume growth with market sh
Slide 13: Quality Focused State of the Art Manufacturing Facilities
Quality Focused State of the Art Manufacturing Facilities Gujarat – OSD (General Himachal Pradesh – OSD & Total Installed Capacity Liquid Facility Facility) Installed capacity of ~403 Mn Installed capacity of ~1.25 Formulations* tablets/capsules & 10 Mn liquid Bn* tablets/capsules & 20 bottles Mn sa
Slide 14: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and FY27 Annexures Management
Slide 15: Indian Pharmaceutical Market: High-Growth Landscape
Indian Pharmaceutical Market: High-Growth Landscape IPM is poised to grow at CAGR of 8-9% till FY30 Growth drivers for domestic formulations industry INR Trillion 3.1 2.3 Improving life expectancy and changing 2.1 1.8 1.9 demographic profile 1.5 1.5 01 Rising prevalence of chronic diseases FY20 FY21
Slide 16: CORONA Remedies: Demonstrated 1.9x Growth compared to IPM
CORONA Remedies: Demonstrated 1.9x Growth compared to IPM CORONA growth compared to IPM [1] Growth driven by volume, price and new product launches IPM CORONA 1.9x 1.5x 18.44% 8.74% 5.0x 6.30% 5.64% 9.81% 1.2x 3.40% 2.91% 1.26% IPM [1] CORONA Remedies Volume Growth Price Growth NI (2) growth Rank Pr
Slide 17: Cementing position in Chronic segment with focus on four Key Therapies
Cementing position in Chronic segment with focus on four Key Therapies Women’s Healthcare Cardio-Diabeto Pain Management Urology CORONA Remedies vs. 2.5x 1.7x 1.4x 1.8x IPM [1] 23.3% 21.6% 17.8% 26.7% 12.3% 12.5% 14.9% 9.4% IPM CORONA IPM CORONA IPM CORONA IPM CORONA Women’s Healthcare Cardio-Diabet
Slide 18: Focussed presence in the 'Middle of the Pyramid' segment
Focussed presence in the “Middle of the Pyramid’’ segment Specialty-wise prescription split IPM 8% Super 12% Strategic focus on Specialist specialist and super- specialist doctors in the ‘middle of the pyramid’; resulting in a higher prescription contribution compared with IPM 35% 35% Specialist 55%
Slide 19: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and FY27 Annexures Management
Slide 20: 'Engine' Brands approach with Successful Scaling Up of Brands
“Engine” Brands approach with Successful Scaling Up of Brands 33 Engine Brands Established track record of building and scaling brands Brands with Sales ~76.3% 32 >INR 10 Crs 40 Contribution to Domestic Sales MAT Jun-26 2 ~19.5% 1 8 CAGR over 2 MAT Jun-23 to MAT Jun-26 9 Brands 11 No. of Top 5 Brand
Slide 21: Acquisition & Strategic Collaborations for India Business
Acquisition & Strategic Collaborations for India Business Strategic collaborations for India Significantly scaled-up acquired brands Business Sr. No Acquired From Brands GSK Pharmaceuticals Limited Dilo Ferring Pharmaceuticals, Switzerland 1 Stelbid In-Licensing Arrangement for certain products in G
Slide 22: Strategic Portfolio Diversification & Brand Development
Strategic Portfolio Diversification & Brand Development Chronic v/s Acute 28.1% Chronic FY16 45.3% Acute Accelerating growth in 54.7% FY26 chronic therapies - 71.9% Outperforming the IPM Womens Healthcare Pain Management Therapy Wise 23.7% 27.5% 32.8% Cardio Diabeto Strengthening focus on core FY16
Slide 23: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and FY27 Annexures Management
Slide 24: Future Growth Strategies
CORONA Remedies Limited Future Growth Strategies • Improve MR productivity, expanding prescriber base and increasing the number of products Increase market share prescribed per prescriber 1 within the domestic • Intensify engagement with super-specialist prescribers in metro, semi-metro, and urban c
Slide 25: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and FY27 Annexures Management
Slide 26: Professional Senior Management Leading the Way
Professional Senior Management Leading the Way Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Managing Director & CEO Joint Managing Director Whole-Time Director Over 2 decades of experience in the Over 2 decades of experience in the Over 2 decades of experience in th
Slide 27: Experienced Board of Directors
Experienced Board of Directors Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Dr. Kiritkumar Laxmidas Mehta Managing Director & CEO Joint Managing Director Whole-Time Director Chairman and Non-Executive Director Ameetkumar Hiranyakumar Desai Monica Kanuga Shirish Gund
Slide 28: ESG @ CORONA Remedies
ESG @ CORONA Remedies • Existing solar power plant of 1.3 MW at Bhayla Plant and 4.25 MW in Solar Park Spread across 11.9 Acres which saves significant electricity cost E • • Protection of Environment by Tree Plantation, Distribution of Plant Saplings, initiatives like wearing un-ironed clothes Effl
Slide 29: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Profit and Loss (₹ Crores) FY26 FY25 FY24 FY23 Revenue from Operations 1,403.2 1,196.4 1,014.5 884.1 Cost of Goods Sold 260.9 236.5 226.8 211.0 Gross Profit 1,142.2 959.9 787.6 673.1 Gross Margin (%) 81.4% 80.2% 77.6% 76.1% Employee Cost 403.0 346.1 29
Slide 30: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Assets (₹ Crores) Mar-26 Mar-25 Mar-24 Mar-23 Equity & Liabilities (₹ Crores) Mar-26 Mar-25 Mar-24 Mar-23 Non - Current Assets 856.8 591.0 540.7 303.5 Total Equity 746.9 606.3 480.4 408.5 Property, plant and equipment 291.1 198.7 191.0 184.1 Share Capital 61.2 6
Slide 31: Historical Consolidated Abridged Cash Flow Statement
Historical Consolidated Abridged Cash Flow Statement Abridged Cash Flow Statement (₹ Crores) FY26 FY25 FY24 FY23 Net Profit Before Tax 240.4 198.5 118.5 110.9 Adjustments for: Non - Cash Items / Other Investment or Financial Items 44.4 52.3 46.9 22.6 Operating profit before working capital changes 2
Slide 32: Historical Financial Statement
Historical Financial Statement Revenue (₹ Crores) EBITDA (₹ Crores) PAT (₹ Crores) 1,403.2 293.4 199.4 17% 1,196.4 +32% 240.0 +33% 1,014.5 149.4 884.1 154.7 128.0 90.5 84.9 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26* *Excludes onetime statutory impact of New Labor Code Rs.19.1 Cr (P
Slide 33: Historical Financial Ratios
Historical Financial Ratios ROCE (%) ROE (%) 41.3% 40.8% 29.2% 27.5% 31.2% 23.3% 28.4% 20.4% FY23 FY24 FY25 FY26* FY23 FY24 FY25 FY26* OCF/EBITDA (%) Net working Capital Days 101.3% 31 27 80.2% 79.4% 78.2% 23 24 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 *ROE and ROCE for FY26 is annualised & Excludes
Slide 34: Thank You
THANK YOU For further information, please contact: CORONA Remedies Limited Strategic Growth Advisors Private Limited (SGA) CIN: L24231GJ2004PLC044656 CIN: U74140MH2010PTC204285 Ms. Chetna Dharajiya – Company Secretary & Compliance Officer Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / ta